Roche buys Lonza’s Singapore biologics plant
Basel-headquartered Roche has paid fellow Swiss firm Lonza $290m (€203m) for its Singapore biologics plant in a bid to secure long-term manufacturing capacity for biotech cancer drugs.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs